

KLINICKÉ STUDIE

účinek probiotického kmene *Streptococcus Salivarius* K12 obsaženého v produktu OROBACTOS je ověřen mnoha studiemi

Kromě několika menších studií bylo provedeno i několik větších klinických studií ověřujících účinek probiotického kmene *Streptococcus salivarius* K12 obsaženého v produktu OROBACTOS.

Di Pierro et al, 2013, Italy

Clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* in adults. *Expert Opin Biol Ther.* 2013 Mar;13(3):339-43.

Di Pierro et al, 2012, Italy

Preliminary pediatric clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in preventing recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* and recurrent acute otitis media. *Int J Gen Med.* 2012;5:991-7

Ishijima et al, 2012, Japan and New Zealand

Effect of *Streptococcus salivarius* K12 on the in vitro growth of *Candida albicans* and its protective effect in an oral candidiasis model. *Appl Environ Microbiol.* 2012 Apr;78(7):2190-9.

Guglielmetti et al, 2010, Italy

Oral bacteria as potential probiotics for the pharyngeal mucosa. *Appl Environ Microbiol.* 2010 Jun;76(12):3948-58.

Horz et al, 2007, Germany

Distribution and persistence of probiotic *Streptococcus salivarius* K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. *Oral Microbiol Immunol.* 2007 Apr;22 (2):126-30.

Tagg et al, 2006, New Zealand

Oral streptococcal: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections. *International Congress Series*, 2006, Vol 128: 347-350

Wescombe et al, 2006, New Zealand

Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. *Appl. Environ. Microbiol.* 2006 Feb 72(2):1459-1466.

Tagg et al, 2004, New Zealand

Prevention of streptococcal pharyngitis by anti-*Streptococcus pyogenes* bacteriocin-like inhibitory substances produced by *Streptococcus salivarius*. *Indian J Med Res.* 2004 May;119 Suppl:13-6.

Dierksen et al, 2000, New Zealand

The influence of indigenous bacteriocin-producing *Streptococcus salivarius* on the acquisition of *Streptococcus pyogenes* by primary school children in Dunedin, New Zealand. In: *Streptococci and streptococcal diseases entering the new millennium.* 2000 p81-85.

DENTAL HEALTH

Burton et al, 2013, New Zealand

Influence of the probiotic *Streptococcus salivarius* strain K12 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. J. Med. Microbiol. 2013 62:DOI 10.1099/jmm.0.056663-0

James & Tagg, 1991, New Zealand

The prevention of dental caries by BLIS-mediated inhibition of mutans streptococci. N Z Dent J. 1991 Jul;87(389):80-3.

UPPER RESPIRATORY TRACT INFECTIONS

Fiedler et al, 2013, Germany

Protective mechanisms of respiratory tract Streptococci against *Streptococcus pyogenes* biofilm formation and epithelial cell infection. Appl Environ Microbiol. 2013 Feb;79(4):1265-76.

Di Pierro et al, 2012, Italy

Preliminary pediatric clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in preventing recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* and recurrent acute otitis media. Int J Gen Med. 2012;5:991-7

Santagati et al, 2012, Italy

Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol Med Microbiol 2012 65:23-31

Power et al, 2008, New Zealand

Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic *Streptococcus salivarius* K12. Eur J Clin Microbiol Infect Dis. 2008 Jun 17.

HALITOSIS

Masdea et al, 2012, Switzerland

Antimicrobial activity of *Streptococcus salivarius* K12 on bacteria involved in oral malodour. Arch Oral Biol. 2012 Aug;57(8):1041-7.

Burton et al, 2006, New Zealand

A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters, J Appl Microbiol. 2006 Apr; 100(4):754-64.

Kazor et al, 2003, USA

Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 2003 Feb;41(2):558-563

SAFETY

Barretto et al, 2012, Switzerland

Genome sequence of the lantibiotic bacteriocin producer *Streptococcus salivarius* strain K12. J Bacteriol. 2012 Nov;194(21):5959-60.

Burton et al, 2011, New Zealand and USA

Evaluation of safety and human tolerance of the oral probiotic *Streptococcus salivarius* K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011 Sep;49(9):2356-64.

Heng et al, 2011, New Zealand

Genome sequence of the bacteriocin-producing oral probiotic *Streptococcus salivarius* K12 strain M18. *J. Bact.* 2011 Nov 193:6402-6403

Burton et al, 2010, New Zealand

Extended safety data for the oral cavity probiotic *Streptococcus salivarius* K12. *Probiotics and Antimicro. Prot.* 2010 2:135-144.

Burton et al, 2006, New Zealand

Safety assessment of the oral cavity probiotic *Streptococcus salivarius* K12. *Appl Environ Microbiol.* 2006 Apr;72(4):3050-3.

IMMUNITY

Groeger et al, 2011, Germany

B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by *Porphyromonas gingivalis*. *Immunobiology.* 2011 Dec;216(12):1302-10.

Cosseau et al, 2008, Canada and United Kingdom

The commensal *Streptococcus salivarius* K12 down-regulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. *Infection and Immunity*, Sept. 2008, p. 4163–4175.

OTITIS MEDIA

Di Pierro et al, 2012, Italy

Preliminary pediatric clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in preventing recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* and recurrent acute otitis media. *Int J Gen Med.* 2012;5:991-7.

Tagg et al, 2003, New Zealand

Bacteriocin-like inhibitory substance production by the normal flora of the nasopharynx: potential to protect against otitis media? *J Med Microbiol.* 2003 Sep;52(Pt 9):829-33.

Wescombe et al, 2006, New Zealand & Canada

Megaplasms encode differing combinations of lantibiotics in *Streptococcus salivarius*, *Antonie Van Leeuwenhoek.* 2006 Oct;90 (3):269-80

Hyink et al., 2007, New Zealand

Salivaricin A2 and the novel antibiotic salivaricin B, are encoded by adjacent loci on a 190 kb transmissible megaplasmid in the oral probiotic strain *Streptococcus salivarius* K12. *Appl Environ Microbiol* 73(4): 1107-13.

Wescombe et al, 2006, New Zealand

Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. *Appl Environ Microbiol.* 2006 Feb;72(2):1459-66.

REVIEWS

Wescombe et al, 2012, New Zealand

Developing oral probiotics from *Streptococcus salivarius*. *Future Microbiol.* 2012 7(12):1355-1371.

Hale et al, 2012, New Zealand

Producing probiotics targeting the oral cavity. Microbiology Australia. 2012 Sept 33(3):103-105.

Burton et al, 2011, New Zealand and Canada

Beneficial microbes for the oral cavity: time to harness the oral streptococci? Beneficial microbes. 2011 June 2(2):93-101

Wescombe et al, 2010, New Zealand

Something old and something new: An update on the amazing repertoire of bacteriocins produced by Streptococcus salivarius K12. Probiotics & Antimicro. Prot. 2010 2:37-45

Tagg, 2009, New Zealand

Streptococcal bacteriocin-like inhibitory substances: some personal insights into the bacteriocin-like activities produced by streptococci good and bad. Probiotics and Antimicro. Prot. 2009 1:60-66.

Wescombe et al, 2009, New Zealand

Streptococcal bacteriocins and the case for Streptococcus salivarius K12 as model oral probiotics. Future Microbial. 2009 4(7):819-35

Tagg et al, 2008, New Zealand

Streptococci as effector organisms for probiotic and replacement therapy. In: Therapeutic Microbiology: Probiotic and Related Strategies. J. Versalovic and M. Wilson, American Society for Microbiology. p61-81.

Tagg, 2007, New Zealand

Application of bacterial pathogens in replacement therapy. In: Patho-Biotechnology. R. Sleator and C. Hill Landes Bioscience.

Heng et al, 2007, New Zealand

The diversity of bacteriocins in gram-positive bacteria. In: Ecology and Evolution. M. Riley and M. Chavan. p45-92.

Tagg et al, 2003, New Zealand

Bacterial replacement therapy: adapting 'germ warfare' to infection prevention, Trends Biotechnol. 2003 May;21 (5):217-23.